Cargando…

Pan-Genotypic Direct-Acting Antiviral Agents for Undetermined or Mixed-Genotype Hepatitis C Infection: A Real-World Multi-Center Effectiveness Analysis

Although the pan-genotypic direct-acting antiviral regimen was approved for treating chronic hepatitis C infection regardless of the hepatitis C virus (HCV) genotype, real-world data on its effectiveness against mixed-genotype or genotype-undetermined HCV infection are scarce. We evaluated the real-...

Descripción completa

Detalles Bibliográficos
Autores principales:	Yen, Hsu-Heng, Chen, Yang-Yuan, Lai, Jun-Hung, Chen, Hung-Ming, Yao, Chih-Ta, Huang, Siou-Ping, Liu, I-Ling, Zeng, Ya-Huei, Yang, Fang-Chi, Siao, Fu-Yuan, Chen, Mei-Wen, Su, Pei-Yuan
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	MDPI 2022
Materias:	Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8999637/ https://www.ncbi.nlm.nih.gov/pubmed/35407462 http://dx.doi.org/10.3390/jcm11071853

Ejemplares similares

Real-World Experience of Chronic Hepatitis C-Related Compensated Liver Cirrhosis Treated with Glecaprevir/Pibrentasvir: A Multicenter Retrospective Study
por: Su, Pei-Yuan, et al.
Publicado: (2021)

Long-Term Hepatitis B Surface Antigen Profile and Seroclearance Following Antiviral Treatment: A Single-Center, Real-World Cohort Study
por: Huang, Chih-Wen, et al.
Publicado: (2023)

Direct-acting antiviral treatment for Hepatitis C Virus in geriatric patients: a real-world retrospective comparison between early and late elderly patients
por: Yen, Hsu-Heng, et al.
Publicado: (2021)

Strategy for the Micro-Elimination of Hepatitis C among Patients with Diabetes Mellitus—A Hospital-Based Experience
por: Su, Pei-Yuan, et al.
Publicado: (2021)

Viral dynamics among HCV infected patients with different genotypes treated with genotypic specific or pan-genotypic direct-acting antiviral agent combinations
por: Paolucci, Stefania, et al.
Publicado: (2019)

Recent Information on Pan-Genotypic Direct-Acting Antiviral Agents for HCV in Chronic Kidney Disease
por: Fabrizi, Fabrizio, et al.
Publicado: (2022)

Real-world effectiveness of direct-acting antivirals in people living with human immunodeficiency virus and hepatitis C virus genotype 6 infections
por: Sun, Hsin-Yun, et al.
Publicado: (2022)

Pan-genotypic direct-acting antivirals for patients with hepatitis C virus infection and chronic kidney disease stage 4 or 5
por: Liu, Chen-Hua, et al.
Publicado: (2022)

Chronic Hepatitis B Relapse Rates after Cessation of Tenofovir Alafenamide and Entecavir Therapy
por: Huang, Chih-Wen, et al.
Publicado: (2023)

Radiation Exposure among Patients with Inflammatory Bowel Disease: A Single-Medical-Center Retrospective Analysis in Taiwan
por: Yang, Chen-Ta, et al.
Publicado: (2022)

Evaluation of non-alcoholic fatty liver disease in patients with inflammatory bowel disease using controlled attenuation parameter technology: A Taiwanese retrospective cohort study
por: Yen, Hsu-Heng, et al.
Publicado: (2021)

Mixed cryoglobulinemic membranoproliferative glomerulonephritis due to monoclonal gammopathy of undetermined significance: A case report
por: Hsu, Jung-Hui, et al.
Publicado: (2018)

PanSNPdb: The Pan-Asian SNP Genotyping Database
por: Ngamphiw, Chumpol, et al.
Publicado: (2011)

Machine-Learning Algorithm for Predicting Fatty Liver Disease in a Taiwanese Population
por: Chen, Yang-Yuan, et al.
Publicado: (2022)

Management of hepatitis C genotype 4 in the directly acting antivirals era
por: Hathorn, Emma, et al.
Publicado: (2016)

Comparison of Adverse Events of Different Endoscopic Ultrasound-Guided Tissue Acquisition Methods: A Single-Center Retrospective Analysis
por: Lin, Yen-Chih, et al.
Publicado: (2022)

Efficacy and Safety of Sofosbuvir-Based Direct-Acting Antiviral Agents Treatment for Patients with Genotype 3/6 Hepatitis C Virus Infection
por: Mei, Yong-yu, et al.
Publicado: (2020)

Rapid decline of noninvasive fibrosis index values in patients with hepatitis C receiving treatment with direct-acting antiviral agents
por: Hsu, Wei-Fan, et al.
Publicado: (2019)

Retrieval of lost patients in the system for hepatitis C microelimination: a single-center retrospective study
por: Yen, Hsu-Heng, et al.
Publicado: (2021)

Metabolic Dysfunction-Associated Fatty Liver Disease in Taiwanese Patients with Inflammatory Bowel Disease: A Study in Patients with Clinical Remission
por: Hsiao, Shun-Wen, et al.
Publicado: (2023)

Economic evaluation of pan-genotypic generic direct-acting antiviral regimens for treatment of chronic hepatitis C in Iran: a cost-effectiveness study
por: Tasavon Gholamhoseini, Mohammad, et al.
Publicado: (2022)

High-risk human papillomavirus genotyping in women with atypical squamous cells of undetermined significance
por: Ittiamornlert, Pornporm, et al.
Publicado: (2023)

Unbranched rod-like RNA is required for RNA editing of hepatitis delta virus genotype 2 and genotype 4
por: Hsu, Chao-Wei, et al.
Publicado: (2023)

Draft Genome Sequence of Mycobacterium tuberculosis Clinical Strain W06, a Prevalent Beijing Genotype Isolated in Taiwan
por: Liao, Yu-Chieh, et al.
Publicado: (2015)

Treatment of hepatitis C virus genotype 3 infection with direct-acting antiviral agents
por: Zanaga, L.P., et al.
Publicado: (2016)

Performance of Different Combination Models of High-Risk HPV Genotyping in Triaging Chinese Women With Atypical Squamous Cells of Undetermined Significance
por: Guo, Zhen, et al.
Publicado: (2019)

Clinical utility of hepatitis C virus core antigen assay in the monitoring of direct-acting antivirals for chronic hepatitis C
por: Lin, Sheng Feng, et al.
Publicado: (2020)

Glecaprevir–pibrentasvir for chronic hepatitis C: Comparing treatment effect in patients with and without end-stage renal disease in a real-world setting
por: Yen, Hsu-Heng, et al.
Publicado: (2020)

Genotype-specific methylation of HPV in cervical intraepithelial neoplasia
por: Hsu, Yaw-Wen, et al.
Publicado: (2017)

Augmenting central arterial stiffness following eradication of HCV by direct acting antivirals in advanced fibrosis patients
por: Cheng, Pin-Nan, et al.
Publicado: (2019)

Direct-Acting Antivirals in Chronic Hepatitis C Genotype 4 Infection in Community Care Setting
por: Gayam, Vijay, et al.
Publicado: (2018)

Economic evaluation of direct‐acting antivirals for the treatment of genotype 3 hepatitis C infection in Singapore
por: Wong, Yu‐Jun, et al.
Publicado: (2019)

Glecaprevir/Pibrentasvir in patients with hepatitis C virus genotype 1 or 4 and past direct‐acting antiviral treatment failure
por: Poordad, Fred, et al.
Publicado: (2018)

Direct-Acting Antivirals Reduce the De Novo Development of Esophageal Varices in Patients with Hepatitis C Virus Related Liver Cirrhosis
por: Hsieh, Yung-Yu, et al.
Publicado: (2023)

Effectiveness of sofosbuvir based direct-acting antiviral regimens for chronic hepatitis C virus genotype 6 patients: Real-world experience in Vietnam
por: Nguyen, Dung Thanh, et al.
Publicado: (2020)

Potent Antiviral Activities of the Direct-Acting Antivirals ABT-493 and ABT-530 with Three-Day Monotherapy for Hepatitis C Virus Genotype 1 Infection
por: Lawitz, Eric J., et al.
Publicado: (2016)

Development of Ultrapure and Potent Tannic Acids as a Pan-coronal Antiviral Therapeutic
por: Shih, Po-Chang, et al.
Publicado: (2022)

Glecaprevir and pibrentasvir for 12 weeks for hepatitis C virus genotype 1 infection and prior direct‐acting antiviral treatment
por: Poordad, Fred, et al.
Publicado: (2017)

A retrospective study of prevalence and pattern of international consensus on ANA patterns among patients with hepatitis C virus infection
por: Hsiao, Shun-Wen, et al.
Publicado: (2022)

Comparison of Machine Learning Models and the Fatty Liver Index in Predicting Lean Fatty Liver
por: Su, Pei-Yuan, et al.
Publicado: (2023)

Cannot write session to /tmp/vufind_sessions/sess_me3dmkgkd5f49442q2b9c0iv6a